#USA #South San Francisco #Human Longevity #Ovarian Cancer #Avantect

Human Longevity, Inc. Expands Cancer Prevention Initiative

In a groundbreaking effort, Human Longevity, Inc. (HLI), a pioneer in precision health, announced an expansion of its ambitious $1 million cancer prevention pledge aimed at late-stage ovarian cancer. This initiative underscores HLI's commitment to the necessity of early detection and sophisticated diagnostics in healthcare. The expanded program will provide up to $1 million in clinical support for any qualified participant diagnosed with late-stage ovarian cancer while enrolled in HLI's Executive Health Program or its extensive network of over 100 Longevity Programs.

Advancing Early Detection with Avantect® Liquid Biopsy

HLI's Executive Health Program has already facilitated the screening of more than 10,000 members, utilizing an advanced AI-driven platform that integrates genomics, imaging, and biomarkers. A notable development in Ovarian cancer prevention is the incorporation of the Avantect® Ovarian Cancer Liquid Biopsy—a pioneering and clinically validated blood test that boasts a high negative predictive value (NPV) for detecting early-stage ovarian cancer. By identifying the signals from tumor-derived cell-free DNA, the Avantect® test is set to enhance HLI's multifaceted detection strategy critically.

The program’s comprehensive approach includes:

• - Whole genome sequencing with a focus on BRCA1/2 and other hereditary cancer-related genes.
• - Whole-body MRI including specialized pelvic imaging.
• - Multi-cancer early detection (MCED) blood tests.
• - Continuous monitoring of symptoms and biomarkers.

By combining these methodologies, HLI aims to significantly improve the early detection of ovarian cancer, ultimately leading to better outcomes for women.

How the Initiative Functions

To qualify for the initiative, participants must remain continually enrolled in the Executive Health Program or one of the affiliated Longevity Programs, completing annual screenings tailored specifically for ovarian cancer, which will include the Avantect® liquid biopsy as part of their clinical routine. Should a member be diagnosed with late-stage ovarian cancer during their active membership, they will benefit from support that covers treatment, clinical navigation, and expert consultations with leading gynecologic oncology specialists, up to a value of $1 million.

Dr. Wei-Wu He, Executive Chairman of HLI, emphasized the proactive approach to cancer treatment, suggesting, "Prevention is the future of medicine. Our initiative, featuring the Avantect® liquid biopsy as part of our Executive Health Program, fortifies our capability to detect cancer in its early stages. Even in instances where detection may falter, we ensure our members have access to premier medical care."

A Commitment to Women’s Health

Ovarian cancer is notorious for being one of the most fatal gynecologic malignancies, primarily due to late-stage diagnoses. HLI is repositioning how women's health and cancer prevention are approached through state-of-the-art applications like Avantect®, advanced imaging technologies, and AI-enabled analytics within the Executive Health Program. This initiative not only represents a financial promise but also serves as a crucial call to action for precision preventive care.

HLI's mission aims to transition healthcare into a proactive discipline, equipping members with the most sophisticated tools available for early detection and intervention.

About Human Longevity, Inc.

Human Longevity, Inc. is a driven biotechnology firm that merges genomics, artificial intelligence, and multimodal diagnostics to enhance human healthspan. Their signature Executive Health Program alongside the 100+ Longevity Programs provides thorough, data-centric evaluations that focus on the identification and prevention of diseases long before symptoms emerge. For more detailed information or to take part in the program, visit www.humanlongevity.com or this link.

For media inquiries, contact: [email protected].